AbbVie, Parkinson's disease and Phase III
AbbVie’s $8.7B Cerevel Buy Starts to Pay off With Phase III Parkinson’s Win
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, will help AbbVie as it builds a regulatory case for the D1/D5 dopamine receptor agonist.
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial
The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three years.
AbbVie's dopamine-focused Parkinson's treatment reduces disease burden in phase 3 trial
AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That trial is testing the drug as a flexible-dose monotherapy.
AbbVie Parkinson’s drug helps improve symptoms in late-stage study
AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate symptoms and improve quality of life in a late-stage study.
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug showed significant improvements in patient symptoms, meeting primary and secondary endpoints.
AbbVie: Tavapadon Meets Primary, Secondary Endpoints In Phase 3 Trial In Early Parkinson's Disease
Drugmaker AbbVie (ABBV) announced Thursday positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a
AbbVie's Parkinson's disease drug meets main goal in late-stage trial
AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company said on Thursday.Patients showed a statistically significant improvement when two fixed doses of the drug,
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), ACADIA ...
Zacks.com on MSN2h
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...
AbbVie Inc. stock rises Thursday, still underperforms market
Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
AbbVie ABBV has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual ...
Bristol Myers Squibb Vs. AbbVie Stock
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...
AbbVie Inc. stock outperforms competitors despite losses on the day
AbbVie Inc. closed $6.44 short of its 52-week high ($199.95), which the company achieved on September 3rd.
Hosted on MSN1d
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
In the latest market close, AbbVie (ABBV) reached $191.26, with a -1.16% movement compared to the previous day. The stock's performance was behind the S&P 500's daily loss of 0.19%. Meanwhile, the Dow ...
Abbvie Worker Advances Suit Over Family Medical History Queries
Abbvie Inc. failed to defeat a proposed class action by a Chicago-area technician who says he and other workers were ...